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ABSTRACT
Objective. To evaluate the efficacy and tolerability of
letrozole plus lapatinib versus letrozole plus placebo in
women with hormone receptor (HR)
 human epider-
mal growth factor receptor (HER)-2
 tumors receiving
first-line therapy for metastatic breast cancer (MBC).
Patients and Methods. Postmenopausal women (n 
1,286) with HR
 MBC were randomized to daily oral
treatment with letrozole (2.5 mg) plus lapatinib (1,500
mg) versus letrozole (2.5 mg) plus placebo. Of the 1,286
patients enrolled in the phase III study, 219 had
HER-2
 tumors. The primary endpoint was progres-
sion-free survival (PFS) in HER-2
 patients.
Results. Results in the HR
 HER-2
 population (n 
219)arepresented.Theadditionoflapatinibtoletrozole
resultedinasignificantlylowerriskfordiseaseprogres-
sion than with letrozole alone (hazard ratio, 0.71; 95%
confidence interval, 0.53–0.96). The PFS time was 8.2
months, versus 3.0 months. The objective response rate
(ORR) (28% versus 15%) and clinical benefit rate
(CBR)(48%versus29%)werealsosignificantlygreater
in lapatinib-treated women. The most common adverse
events in the lapatinib group were diarrhea (68%) and
rash (46%), primarily grade 1 and 2.
Conclusions. The addition of lapatinib to letrozole is
well tolerated and leads to a significantly greater PFS
time, ORR, and CBR than with letrozole alone in
women with MBC who coexpress HR and HER-2. The
Oncologist 2010;15:122–129
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Estrogen deprivation with agents such as aromatase inhib-
itors and tamoxifen is standard treatment for postmeno-
pausal estrogen receptor (ER)
 breast cancer. However,
resistance invariably develops, leading to disease relapse.
Endocrine therapy–induced upregulation of signaling path-
ways of the epidermal growth factor receptor (EGFR) fam-
ily of receptors—ErbB-1 (EGFR) and ErbB-2 (human
epidermalgrowthfactorreceptor[HER]-2)—andenhanced
ER-mediatedtranscription,whichleadtoamoreaggressive
phenotype, are key adaptive changes associated with estro-
gen resistance [1, 2].
Just as estrogen deprivation is the cornerstone of treat-
ment for ER
 postmenopausal breast cancer, anti-HER-2
therapy is the treatment of choice for HER-2
 breast can-
cer. Dramatic clinical success is achieved when the HER-2
signaling pathway is blocked in women with breast cancer
that overexpresses HER-2 [3–6].
Approximately 50% of HER-2
 breast cancers are hor-
mone receptor (HR)
, [4, 5, 7, 8] and HER-2 positivity is
considered a marker of estrogen resistance [9, 10]. There-
fore, dual treatment for tumors that overexpress both re-
ceptors is a logical approach. A randomized trial was
conducted in women with HR
 and HER-2
 metastatic
breast cancer (MBC) to determine the impact of combined
treatmentwiththeanti-HER-2monoclonalantibodytrastu-
zumabandthearomataseinhibitoranastrozoleversusanas-
trozole alone. The combination was associated with a
median progression-free survival (PFS) duration of 4.8
months, versus 2.4 months for anastrozole alone [7]. Other
clinicalresearchalsosupportstheroleofcombinationtreat-
ment with HER-2 inhibitors and endocrine blockade in
HR
 breast cancer [11, 12].
Synergyhasbeendemonstratedwiththecombinationof
tamoxifen and lapatinib in models of endocrine resistance
[13, 14]. A phase I study demonstrated no pharmacokinetic
interactions between lapatinib and the aromatase inhibitor
letrozole [15]. To further examine the role of estrogen de-
privation plus anti-HER-2 therapy, we compared first-line
therapy using letrozole plus placebo with letrozole plus
lapatinib in a phase III study conducted in postmenopausal
women with HR
 MBC [16]. Full results of this phase III
study have been published [16]. Results in the subgroup of
postmenopausal women with HR
 HER-2
 MBC are pre-
sented here.
MATERIALS AND METHODS
Eligibility Criteria
Postmenopausal women with ER
 or progesterone recep-
tor–positive (i.e., HR
), histologically confirmed, ad-
vancedbreastcancerorMBC(stageIIIb/corstageIV)were
enrolled between December 9, 2003 and December 29,
2006.Resultsarepresentedhereforenrolledwomenwhose
primary or metastatic tumor was also HER-2
. A HER-2

tumor was defined as fluorescence in situ hybridization
(FISH)
 (ratio 2), 3 staining intensity by immunohis-
tochemistry (IHC), or 2 staining intensity by IHC and
FISH
,asdescribedpreviouslyformethodsperformedina
commercial laboratory [17].
Prior therapy for advanced or metastatic disease was
prohibited, but prior neoadjuvant/adjuvant chemotherapy,
antiestrogens, and radiotherapy were allowed. Adjuvant
aromataseinhibitorsandtrastuzumabwerepermittedifdis-
continued at least 1 year prior to study entry. A good per-
formance status (Eastern Cooperative Oncology Group
[ECOG] performance status score of 0–1) and normal or-
gan function were required, with cardiac ejection fraction
within the institutional range of normal. Extensive symp-
tomatic visceral disease and current or past central ner-
vous system metastases were causes for exclusion.
Enrollment required archived tumor tissue for use in bi-
omarker analyses.
Ethics approval was obtained from appropriate local
ethics committees and the study was conducted in accor-
dance with the Declaration of Helsinki and Good Clinical
Practice Guidelines. All patients signed informed consent
documents before enrollment in the study. This study was
funded by GlaxoSmithKline.
Trial Design
This was a randomized, double-blind, controlled, parallel-
group, multicenter, phase III study with stratification by in-
terval since completion of prior adjuvant antiestrogen
therapy (at least 6 months or no prior therapy versus 6
months) and location of metastatic sites (soft tissue or vis-
ceral versus bone-only disease). Measurable disease was
not required at study entry. Eligible patients were random-
ized to once-daily oral treatment with letrozole (2.5 mg)
plus lapatinib (1,500 mg) or to the same dose of letrozole
plusamatchinglapatinibplacebo.Lapatinibdosageadjust-
ments were made in accordance with the U.S. Food and
DrugAdministration–approvedlapatinibprescribinginfor-
mation[18].Nodosageadjustmentswereallowedforletro-
zole. Patients were continued on the assigned treatment
until disease progression or withdrawal from study and
werenotpermittedtocrossovertothealternatetreatmentin
the event of disease progression. Permanent withdrawal
fromstudytreatmentwasrequiredforunacceptabletoxicity
orgrade3or4interstitialpneumonitis,hepatoxicity,orcar-
diac dysfunction.
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The primary endpoint was investigator-assessed PFS in the
HER-2
 population determined according to the Response
Evaluation Criteria in Solid Tumors (RECIST) [19]. The
PFS time was defined as the time from randomization until
the earliest date of disease progression or death resulting
from any cause. The overall response rate (ORR), clinical
benefit rate (CBR), overall survival (OS) time, and safety
were secondary endpoints. The CBR was defined as a con-
firmed complete response, partial response, or stable dis-
ease for at least 6 months.
Initially, toxicity was assessed every 4 weeks according
totheNationalCancerInstituteCommonTerminologyCri-
teria for Adverse Events (version 3.0), and cardiac function
was assessed every 8 weeks. Beginning week 108, toxici-
tiesandcardiacfunctionwereassessedevery12weeks.Ef-
ficacywasassessedevery12weeksandatthetimeofstudy
treatment withdrawal, after which patients were followed
only for survival.
TheprimaryendpointofPFSintheHER-2
population
was powered at 80% to detect a hazard ratio (HR) of 0.645
with an  of 0.05 with 173 events. PFS and OS were sum-
Figure 1. Study design, populations, randomization, and assessment of events.
Abbreviations: HER-2, human epidermal growth factor receptor 2; ITT, intent to treat; MBC, metastatic breast cancer; PD,
progressive disease; PFS, progression-free survival; po, orally.
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log-ranktestusedforcomparisonsbetweentreatmentarms.
Cox regression analysis was used to assess the prognostic
significanceofPFSfortheknownprognosticbaselinechar-
acteristics after retaining treatment and stratification fac-
tors: age, ECOG performance status score (0 or 1),
numberofmetastaticsites,siteofdisease(boneonlyorvis-
ceralandsofttissue),intervalsincepriorchemotherapy,in-
terval since prior adjuvant antiestrogen therapy, disease-
free interval, and serum HER-2 (extracellular domain
[ECD]) at baseline (15 ng/ml versus 15 ng/ml). The
Kaplan–Meier method with stratified log rank was used to
Table 1. Baseline characteristics
Characteristic
HR
 HER-2
 patients
Letrozole  placebo
(n  108)
Letrozole  lapatinib
(n  111)
Age, yrs
Median (range) 59 (45–87) 60 (44–85)
ECOG performance status score, n (%)
0 51 (47%) 59 (53%)
1 57 (53%) 51 (46%)
HR status as assessed by local laboratory, n (%)
ER
 PgR
 75 (69%) 76 (68%)
ER
 PgR
 27 (25%) 23 (21%)
ER
 PgR unknown 4 (4%) 9 (8%)
ER
 PgR
 2 (2%) 3 (3%)
Stage of disease, n (%)
IIIB or IIIc 7 (6%) 5 (5%)
IV 101 (94%) 106 (95%)
n of metastatic sites, n (%)
3 42 (39%) 47 (42%)
Site of disease, n (%)
Bone only 18 (17%) 16 (14%)
Visceral or soft tissue 90 (83%) 95 (86%)
Liver 37 (34%) 33 (30%)
Lung 40 (37%) 43 (39%)
Lymph node 43 (40%) 57 (51%)
Soft tissue 31 (29%) 35 (32%)
Other 18 (17%) 19 (17%)
Previous therapy, n (%)
Endocrine 62 (57%) 60 (54%)
Tamoxifen or toremifene only 60 (56%) 59 (53%)
Aromatase inhibitor only 1 (1%) 1 (1%)
Chemotherapy 51 (47%) 61 (55%)
Anthracycline only 38 (35%) 41 (37%)
Anthracyclines and taxanes 9 (8%) 9 (8%)
Other 4 (4%) 11 (10%)
Biologic therapy (any) 1 (1%) 1 (1%)
Interval since prior adjuvant antiestrogen therapy
6 mos or no prior therapy 67 (62%) 73 (66%)
6 mos 41 (38%) 38 (34%)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; HER-2, human epidermal growth
factor receptor 2; HR, hormone receptor; PgR, progesterone receptor.
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populations within the HER-2
 cohort to compare treat-
ment arms within each subpopulation: patients without
boneastheonlysiteofmetastasis,age,presenceorabsence
of liver metastasis, number of metastatic sites, ECOG per-
formance status, and prior hormonal therapy.
RESULTS
In total, 1,286 HR
 patients were enrolled, of whom 219
hadHR
HER-2
MBC(Fig.1).Ofthese219patients,111
wererandomizedtotheletrozolepluslapatinibarmand108
wereintheletrozoleplusplaceboarm.Baselinediseaseand
patient characteristics were well balanced between arms.
Most patients had stage IV disease and visceral or soft tis-
sue metastases. Approximately half of the patients in each
arm received prior antiestrogen therapy and/or prior che-
motherapy. Approximately one third of the patients re-
ceived adjuvant antiestrogen therapy within 6 months of
study entry (Table 1).
Efficacy
Patients were followed for a median of 1.9 years. The me-
dian PFS times in HR
 HER-2
 patients were 3.0 months
in the letrozole plus placebo group and 8.2 months in the
letrozole plus lapatinib group. The HR for the risk for pro-
gression was 0.71 favoring the lapatinib group (95% confi-
dence interval [CI], 0.53–0.96; p  .019) (Fig. 2). When
adjusted for baseline prognostic factors, the stepwise Cox
regression analysis for PFS confirmed the benefit of letro-
zole plus lapatinib over letrozole alone (HR, 0.65; 95% CI,
0.47–0.89; p  .008). Younger age, a performance status
score of 0, and baseline HER-2 ECD 15 ng/ml measured
by quantitative enzyme-linked immunosorbent assay were
identified as significant predictors of PFS.
Aretrospectiveanalysiswithinknownprognosticfactor
subpopulations showed consistently longer PFS time with
letrozole plus lapatinib than with letrozole alone in the fol-
lowinggroups:patientswithoutboneastheonlysiteofme-
tastasis, patients with and without liver metastases, patients
with fewer than three or three or more metastatic sites, pa-
tients with an ECOG performance status score of 0 or 0,
andpatientshavingreceivedpriorhormonaltherapyfor6
months or for 6 months/none (Fig. 3). Patients with bone
as the only site of metastasis were not included because of
the small subpopulation size.
The ORR was also significantly higher in lapatinib-
treated patients (28%, versus 15%; odds ratio [OR], 0.4;
95% CI, 0.2–0.9; p  .021), as was the CBR (48%, versus
29%; OR, 0.4; 95% CI, 0.2–0.8; p  .003) (Table 2). With
a 47% death rate and 41% of patients still being followed
for survival, the median OS times were 32.3 months in the
letrozole plus placebo group and 33.3 months in the letro-
zole plus lapatinib group.
Safety
In total, 219 HR
 HER-2
 patients were included in the
safety analysis. Two subjects randomized to the letrozole
plus placebo arm actually received letrozole plus lapatinib,
thus the safety population reports on 106 and 113 patients,
respectively. Adverse events were reported in 77% of pa-
tients in the letrozole plus placebo group and in 96% of pa-
tients in the letrozole plus lapatinib group. In both groups,
adverse events were primarily grade 1 and 2. The most
common adverse events in the letrozole plus lapatinib
group were diarrhea (68%), rash (46%), nausea (27%), fa-
tigue (22%), and arthralgia (18%), and in each case, with
the exception of arthralgia, the incidence was greater than
in the letrozole plus placebo group (Table 3). Although
grade 3 and 4 events were rare (no individual grade 4 event
was reported in more than one patient in either group), they
Figure 2. Progression-free survival in the human epidermal growth factor receptor (HER)-2
 population.
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most prominent grade 3 event was diarrhea, reported in 7%
of patients treated with letrozole plus lapatinib. No action
(dose interruption or reduction) was required in most cases
of diarrhea (93%). In a small number of cases, diarrhea was
managed by dose reduction (2%) or temporary interruption
(4%). No patient required drug withdrawal as a result of di-
arrhea. There was one investigator-assessed treatment-
related death in the letrozole plus lapatinib arm and none in
the letrozole plus placebo arm.
Alanine aminotransferase was increased in 6% of pa-
tients in the placebo group and in 11% of patients in the
lapatinib group. Grade 1 or 2 hyperbilirubinemia was re-
ported in 4% of lapatinib-treated patients. Details of ad-
verse events are provided in Table 3.
A relative reduction in left ventricular ejection fraction
20% and below the institutional normal limit was re-
portedinonepatientreceivingletrozoleplusplaceboand
in three patients receiving letrozole plus lapatinib. None
of the HER-2
 patients experienced a symptomatic car-
diac event.
DISCUSSION
Identification of mechanisms of resistance often serves as
the basis for the development of more effective therapies.
AnassociationbetweentumorHER-2positivityandlackof
response to endocrine therapy has been observed [9, 10].
The role of growth factors in estrogen resistance was estab-
lished in human breast cancer cells, whereby inhibition of
crosstalk between ER and HER-2 restored the estrogen re-
sponsivenessofER
breastcancercells[2].Moreover,pre-
clinical data suggest that EGFR/HER-2 targeted therapy
combined with endocrine deprivation delays the develop-
ment of resistance [20, 21].
Figure 3. Forest plot of hazard ratio for investigator-evaluated PFS by subgroups of baseline covariates.
Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HER-2, human epidermal growth fac-
tor receptor 2; Met, metastasis; PFS, progression-free survival.
Table 2. Response rate
Letrozole (2.5
mg)  placebo
(n  108)
Letrozole (2.5
mg)  lapatinib
(1,500 mg)
(n  111)
CR 4% 5%
PR 11% 23%
SD 6 mos 14% 20%
CBR 29% 48%
OR, 0.4; 95% CI, 0.2–0.8; p  .003
ORR 15% 28%
OR, 0.4; 95% CI, 0.2–0.9; p  .021
Patients with both measurable and non-measurable
disease are included in this table.
Abbreviations: CBR, clinical benefit rate (confirmed CR
or PR or SD for at least 6 months); CI, confidence
interval; CR, complete response; OR, odds ratio; ORR,
overall response rate (confirmed CR or PR); PR, partial
response; SD, stable disease.
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anism of resistance to endocrine-deprivation therapy to the
development of a combination regimen that addresses the
roles of excess hormones, hormone resistance, and HER-2
overexpression in postmenopausal women with MBC.
Lapatinib is an oral receptor tyrosine kinase inhibitor
that targets HER-2 and has not been associated with signif-
icant symptomatic cardiotoxicity [22]. We combined lapa-
tinib with the aromatase inhibitor letrozole, which has been
shown to have favorable clinical efficacy, compared with
tamoxifen [23].
Theadditionoflapatinibtoletrozoleasfirst-linetherapyin
postmenopausalwomenwithHR
HER-2
MBCledtoasig-
nificantly lower risk for disease progression and longer PFS
time, 8.2 months versus 3.0 months, as well as a higher ORR
and CBR. These results are consistent with the findings in a
similar population in which anastrozole alone was compared
with anastrozole plus trastuzumab [7]. Likewise, benefit for
the combination of lapatinib and letrozole compared with
letrozole alone was seen in all known prognostic factor sub-
populations, including patients who were resistant to prior en-
docrine therapy (i.e., relapsed on or within 6 months of
adjuvant tamoxifen), and those with liver metastases or more
than three sites of metastatic disease. This suggests, therefore,
that dual treatment for suitable patients with tumors that over-
express both HR and HER-2 is a logical approach.
CONCLUSIONS
WomenwithHR
 HER-2
 MBCachievedastatistically
significant 29% lower risk for disease progression when
treated with letrozole plus lapatinib than with letrozole
alone. The combination targeted therapy was well tolerated,
with primarily grade 1 and 2 toxicities. These data support the
use of letrozole plus lapatinib for first-line therapy of patients
with HR
HER-2
MBC. This trial further confirms that sus-
tained HER-2 inhibition provides benefit in patients with
HER-2
 MBC. Moreover, the addition of an oral lapatinib
therapy provides a convenient option for women who receive
oral endocrine therapy for an extended time.
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Table 3. Adverse events
Event
Letrozole  placebo (n  106) Letrozole  lapatinib (n  113)
Grade 1 Grade 2 Grade 3 Grade 4 Total Grade 1 Grade 2 Grade 3 Grade 4 Total
Diarrhea 8% 1% 0 0 8% 38% 23% 7% 0 68%
Rash 8% 1% 0 0 8% 30% 16% 0 0 46%
Nausea 15% 2% 1% 0 18% 20% 7% 0 0 27%
Fatigue 8% 6% 0 0 14% 12% 6% 4% 0 22%
Arthralgia 15% 4% 1% 0 20% 10% 4% 4% 0 18%
Back pain 4% 5% 1 % 0 9 % 8 %7 %2 %0 1 7 %
Vomiting 6% 1% 0 0 7% 12% 4% 1% 0 17%
Headache 7% 4% 1% 0 11% 8% 6% 0 0 14%
Asthenia 8% 2% 0 0 9% 7% 5% 2% 0 14%
Pruritus 2% 2% 1% 0 5% 9% 4% 0 0 13%
Dizziness 8% 0008 % 8 % 4 % 001 2 %
Cough 7% 3% 0 0 9% 8% 3% 0 0 11%
Alopecia 4% 0004 % 1 1 % 0001 1 %
Musculoskeletal pain 3% 2% 0 0 5% 4% 4% 1% 0 10%
Epistaxis 1% 1 % 002 % 7 % 2 % 1% 0 10%
Dyspnea 4% 3% 4% 0 10% 4% 4% 0 1% 9%
Hot flush 9% 3% 0 0 12% 5% 1 % 006 %
Alanine aminotransferase
increase
4% 1% 1% 0 6% 7% 3% 1% 0 11%
Aspartate aminotransferase
increase
3% 0 2% 0 5% 6% 3% 1% 0 10%
Shown are events reported in 10% of patients in any group; discrepancies between values in the total column and the
addition of the incidence rates reported for grades 1, 2, 3, and 4 are a result of mathematical rounding.
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